291 related articles for article (PubMed ID: 14585596)
1. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics.
Zecca L; Zucca FA; Wilms H; Sulzer D
Trends Neurosci; 2003 Nov; 26(11):578-80. PubMed ID: 14585596
[TBL] [Abstract][Full Text] [Related]
2. Neuromelanin of the human substantia nigra: an update.
Zucca FA; Basso E; Cupaioli FA; Ferrari E; Sulzer D; Casella L; Zecca L
Neurotox Res; 2014 Jan; 25(1):13-23. PubMed ID: 24155156
[TBL] [Abstract][Full Text] [Related]
3. The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour.
Zecca L; Zucca FA; Costi P; Tampellini D; Gatti A; Gerlach M; Riederer P; Fariello RG; Ito S; Gallorini M; Sulzer D
J Neural Transm Suppl; 2003; (65):145-55. PubMed ID: 12946053
[TBL] [Abstract][Full Text] [Related]
4. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
[TBL] [Abstract][Full Text] [Related]
5. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
[TBL] [Abstract][Full Text] [Related]
6. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
Zecca L; Tampellini D; Gerlach M; Riederer P; Fariello RG; Sulzer D
Mol Pathol; 2001 Dec; 54(6):414-8. PubMed ID: 11724917
[TBL] [Abstract][Full Text] [Related]
7. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
8. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
9. Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry.
Biesemeier A; Eibl O; Eswara S; Audinot JN; Wirtz T; Pezzoli G; Zucca FA; Zecca L; Schraermeyer U
J Neurochem; 2016 Jul; 138(2):339-53. PubMed ID: 27121280
[TBL] [Abstract][Full Text] [Related]
10. Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra.
Usunoff KG; Itzev DE; Ovtscharoff WA; Marani E
Arch Physiol Biochem; 2002 Oct; 110(4):257-369. PubMed ID: 12516659
[No Abstract] [Full Text] [Related]
11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
12. Neuromelanins in brain aging and Parkinson's disease: synthesis, structure, neuroinflammatory, and neurodegenerative role.
Zucca FA; Capucciati A; Bellei C; Sarna M; Sarna T; Monzani E; Casella L; Zecca L
IUBMB Life; 2023 Jan; 75(1):55-65. PubMed ID: 35689524
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
D'Amato RJ; Lipman ZP; Snyder SH
Science; 1986 Feb; 231(4741):987-9. PubMed ID: 3080808
[TBL] [Abstract][Full Text] [Related]
14. Neuromelanin in parkinsonian disorders: an update.
Martin-Bastida A; Pietracupa S; Piccini P
Int J Neurosci; 2017 Dec; 127(12):1116-1123. PubMed ID: 28460588
[TBL] [Abstract][Full Text] [Related]
15. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
[TBL] [Abstract][Full Text] [Related]
16. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease.
Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M
Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986
[TBL] [Abstract][Full Text] [Related]
17. New face of neuromelanin.
Double KL; Halliday GM
J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
19. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y
Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275
[TBL] [Abstract][Full Text] [Related]
20. Potential neurotoxic "agents provocateurs" in Parkinson's disease.
Collins MA; Neafsey EJ
Neurotoxicol Teratol; 2002; 24(5):571-7. PubMed ID: 12200188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
